お知らせ • May 04
Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2026 Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2026. Location: 169 saxony road, suite 212, california 92024, encinitas United States お知らせ • Apr 07
Kiora Pharmaceuticals, Inc. announced that it has received $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor On April 6, 2026, Kiora Pharmaceuticals, Inc. closed the transaction お知らせ • May 02
Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2025 Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2025. Location: 169 saxony rd., suite 212, california 92024, encinitas, United States お知らせ • Jul 03
Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes Kiora Pharmaceuticals, Inc. announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's Board of Directors. Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company's Board. Ms. Walters-Hoffert will serve as chair of the audit committee and as a member of the compensation committee. Concurrent with her appointment, Ken Gayron, current chair of the audit committee, will step down as a director of the Company's Board due to other work commitments. Ms. Walters-Hoffert was a co-founder of Dar Bioscience, Inc. and following the company's merger with Cerulean Pharma, Inc. in July of 2017, became Chief Financial Officer of the resulting public company. For more than 25 years, Ms. Walters-Hoffert served as an investment banker focused on small-cap public companies in the life science and technology sectors. From 2003 to 2015, Ms. Walters-Hoffert worked at Roth Capital Partners as Managing Director in the Investment Banking Division. Ms. Walters-Hoffert has also held various positions in the corporate finance and investment banking divisions of Citicorp Securities and Oppenheimer &Co, Inc. Ms. Walters-Hoffert currently serves as a director for Flux Power Holdings, Inc. and is a member of the Board of Directors of The Elementary Institute of Science. Additionally, she has served as a member of the Board of Directors of the San Diego Venture Group, as Past Chair of the UCSD Librarian's Advisory Board, and as the Past Chair of the Board of Directors of Planned Parenthood of the Pacific Southwest. Ms. Walters-Hoffert graduated magna cum laude from Duke University with a B.S. in Management Sciences. お知らせ • Mar 26
Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024 Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024, at 10:00 Pacific Standard Time. Location: 332 Encinitas Boulevard, Encinitas california United States Agenda: To consider elect two director nominees as Class III Directors; to consider approve an amendment to the Company's Restated Certificate of Incorporation to effect a reverse stock split of the shares of the Company's Common Stock at a ratio of not less than 1-for-2 and not greater than 1-for-10, with the exact ratio of, effective time of and decision to implement the reverse stock split to be determined by the Board of Directors; to consider approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock to 150,000,000; and to consider other business matters. New Risk • Feb 06
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (316% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€4.72m market cap, or US$5.07m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). お知らせ • Sep 22
Kiora Pharmaceuticals, Inc. Announces Board Changes September 20, 2023 (the “Effective Date”), Paul Chaney resigned as Chairman and member of the Board of Directors of Kiora Pharmaceuticals, Inc. from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the Effective Date. Mr. Chaney did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. In connection with Mr. Chaney’s retirement from the Board, as of the Effective Date, the Board appointed Praveen Tyle, Ph.D. as Chairman of the Board. Additionally, the Board appointed Erin Parsons as Chair of the Compensation Committee of the Board, and appointed Carmine Stengone as a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, in each case effective as of the Effective Date. New Risk • Aug 10
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 9.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.6m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 9.3% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€3.66m market cap, or US$4.03m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years). お知らせ • Aug 02
Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director Kiora Pharmaceuticals, Inc. has appointed Carmine Stengone as an independent member to the Company's board of directors. Stengone currently serves as the President and CEO of Pipeline Therapeutics. With the insights gained throughout his career and most recently from his time leading Pipeline, Stengone will positively impact guidance on strategic decision-making and further clinical development plans. In addition, his extensive network in the industry will help Kiora on multiple fronts. Stengone has served as President and Chief Executive Officer and as a director of Pipeline Therapeutics since 2018. In his role as CEO of Pipeline Therapeutics, he has completed three private rounds of financing totaling) $180 million and executed a)$1 billion collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson &Johnson. He also served as Senior Vice President, Business Development for COI Pharmaceuticals (now Avalon BioVentures Accelerator), and a member of its investment committee, where he helped co-found six new biopharmaceutical companies. While with Avalon Ventures, Carmine served as President and Chief Executive Officer of Avelas Biosciences, Inc. He also served as Vice President of Corporate Development for Afraxis Holdings, Inc. and co-founder and CEO of Afraxis, Inc., a spin-out company from Afraxis Holdings. Earlier in his career, he held positions of increasing responsibility with Phenomix Corporation, Anadys Pharmaceuticals, Inc., and Johnson &Johnson. Carmine received his MBA from the Johnson Graduate School of Management at Cornell University and his M.S. and B.S degrees in chemistry from Duke University and Wake Forest University, respectively. お知らせ • Jul 23
Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market On July 18, 2023, Kiora Pharmaceuticals, Inc. received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive trading days during this 180-day compliance period, unless the Staff exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The compliance period for the Company will expire on January 15, 2024. In the event that the Company does not regain compliance within the 180-day compliance period, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the Minimum Bid Requirement, and provide written notice to the Staff of its intention to cure the deficiency during the second compliance period. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company does not meet the other listing standards, the Staff could provide notice that the Company’s common stock will become subject to delisting. In the event the Company receives notice that its common stock is being delisted, the Nasdaq Listing Rules permit the Company to appeal any such delisting determination by the Staff to a Hearings Panel. The Company intends to actively monitor the closing bid price of its common stock and is evaluating available options to regain compliance with the Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or that the Company will otherwise remain in compliance with the other listing standards for The Nasdaq Capital Market. お知らせ • Feb 16
Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301 In collaboration with Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital announced that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standard treatment. Always at the forefront of full service pharmaceutical and medical device development worldwide, Accelagen's work is first and foremost about accelerating and improving the future of human health. Currently enrolling a small group of RP patients, initial tests are currently being used to determine safety and tolerability of the experimental drug, as well as assessing whether patients have improved vision by evaluating their ability to identify objects, navigate through a mobility course and other ophthalmic and quality-of-life assessments. Also, the study is evaluating how the brain activity changes, specifically looking within the areas of image processing. お知らせ • Feb 08
Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases Kiora Pharmaceuticals, Inc. announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who have signs and symptoms of ocular surface disease. The study is expected to begin enrolling patients in Australia in the first half of 2023. KIO-101 is part of a class of non-steroidal autoimmune disease drugs called DHODH inhibitors, which reduce T-cell proliferation and ongoing proinflammatory cytokine release. Approved systemic drugs in this class, which target systemic disease, generate about $2B in annual revenue. KIO-101 has the potential to affect the local immune response in the eye responsible for the ophthalmic signs and symptoms of these autoimmune diseases. Of the autoimmune diseases that KIO-101 is targeting, the ocular manifestations are found in approximately 3.43M patients in the U.S. The Phase 2 study of KIO-101 is a multicenter, randomized, controlled, double-masked clinical trial in up to 120 patients with ocular signs and symptoms and diagnosed autoimmune diseases, including RA, psoriatic disease, systemic lupus erythematosus, or fibromyalgia. The study will evaluate two concentrations of KIO-101, 0.15 % and 0.30 %. The efficacy endpoints will evaluate a number of established ocular signs and symptoms, including but not limited to corneal staining and changes in the Schirmer's test score at 12 weeks. The study will also evaluate several safety and tolerability measures. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Employee Independent Director Erin Parsons was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. お知らせ • Sep 14
Kiora Pharmaceuticals, Inc. Appoints Melissa Tosca as Executive Vice President of Finance Kiora Pharmaceuticals, Inc. has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company's capital markets strategy and planning. Prior to joining Kiora, Melissa served as Executive Director of Finance and Corporate Treasurer for Neomorph, where she managed the company's finance and accounting functions. She also served as Director of Finance and Accounting at Omniome, building the accounting and finance infrastructure and managing the company's financial operations. Prior to Omniome, she spent nine years at Caris Life Sciences, serving in various leadership roles including Director of Finance and Accounting, Director of Financial Planning and Analysis and Senior Director of Sales Operations. She began her professional career in public accounting at Clifton Gunderson and later moved to Ernst and Young as an Audit Manager. Melissa is a Certified Public Accountant and holds a B.S. in Accounting from the University of Arizona. お知らせ • Aug 26
Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq On August 23, 2022, Nasdaq notified Kiora Pharmaceuticals, Inc. in writing (the Extension Letter") that while the Company had not regained compliance with the Bid Price Rule, it was eligible for an additional 180-day compliance period, or until February 20, 2023, to regain compliance with the Bid Price Rule. Nasdaq's determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on the Company's written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company's common stock, at which point the Company would have an opportunity to appeal the delisting determination to a hearings panel. The Company would remain listed on Nasdaq pending the hearings panel's decision. There can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. The Company intends to continue to consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules, including the implementation of a reverse stock split, if necessary. Board Change • Aug 17
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Employee Independent Director Erin Parsons was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. お知らせ • Aug 16
Kiora Pharmaceuticals, Inc., Annual General Meeting, Sep 23, 2022 Kiora Pharmaceuticals, Inc., Annual General Meeting, Sep 23, 2022, at 10:00 US Eastern Standard Time. Location: offices of Burns & Levinson LLP at 125 High Street Boston United States Agenda: To elect two director nominees as Class I Directors; to approve, on a non-binding advisory basis, the compensation of named executive officers as disclosed in the proxy statement; to approve an amendment to the Company's Restated Certificate of Incorporation to effect a reverse stock split of the shares of the Company's; to approve an amendment to the Company's 2014 Equity Incentive Plan to increase the maximum number of shares authorized for issuance thereunder by 8,000,000 shares and to increase the maximum shares issuable under the evergreen provision; to consider and vote upon an adjournment of the Annual Meeting in order to solicit additional proxies if there are not sufficient shares to be voted in favor of any of the foregoing proposals at the time of the Annual Meeting. お知らせ • Jun 01
Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Kiora Pharmaceuticals, Inc. announced that on May 25, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022, with the Securities and Exchange Commission (“SEC”). This notification has no immediate effect on the listing of the Company’s common stock on the Nasdaq. However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Company’s common stock will be subject to delisting from Nasdaq. As disclosed in the Current Report on Form 8-K filed by the Company on May 23, 2022, the Company’s audit committee concluded that, as a result of inadvertent errors in the accounting for certain contingent consideration, it is appropriate to restate the Company’s previously issued financial statements as of and for the fiscal years ended December 31, 2021 and December 31, 2020 and condensed consolidated interim financial statements as of and for the fiscal periods ended March 31, 2021, June 30, 2021 and September 30, 2021 in a comprehensive amended Annual Report on Form 10-K (the “Amended Form 10-K”) for the fiscal year ended December 31, 2021 with expanded financial information and other disclosures in lieu of filing separate amended annual and quarterly reports for the affected periods during the fiscal years ended December 31, 2021 and December 31, 2020. Given the scope of the process for preparing the Amended Form 10-K, the Company was unable to complete and file the Form 10-Q for the quarter ended March 31, 2022 by the required due date of May 16, 2022. On May 17, 2022, the Company filed a Form 12b-25 Notification of Late Filing with the SEC related to the Form 10-Q. Under the Nasdaq rules, the Company has 60 calendar days, or until July 25, 2022, to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 days from the prescribed due date for filing the Form 10-Q to regain compliance. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. お知らせ • May 18
Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing On 05/17/2022, Kiora Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Apr 01
Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing On 03/31/2022, Kiora Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Feb 15
Kiora Pharmaceuticals, Inc. Announces Resignation of Sarah Romano as Chief Financial Officer, Effective February 25, 2022 Kiora Pharmaceuticals, Inc. announced on February 9, 2022, Sarah Romano, the Chief Financial Officer, notified the Company that she will resign as Chief Financial Officer effective as of February 25, 2022 to pursue another opportunity. お知らせ • Feb 02
Kiora Pharmaceuticals, Inc. Announces Executive Changes Kiora Pharmaceuticals, Inc. announced the appointed Erin Parsons as a member of the Board. Ms. Parsons will serve as a Class III director and will serve until the Company's 2024 Annual Meeting of Stockholders and until her respective successor is duly elected and qualified or her earlier resignation or removal. Effective of January 31, 2022, Stephen From voluntarily resigned as Executive Chairman of the Company and as a member of the Board. Mr. From did not resign as a result of any disagreement regarding the Company's operations, policies or practices. In connection with Mr. From's resignation as Executive Chairman, effective as of January 31, 2022, the Board appointed Paul Chaney as non-executive Chairman of the Board, and Mr. Chaney ceased serving as Lead Independent Director upon his appointment as Chairman. Breakeven Date Change • Jan 20
No longer forecast to breakeven The 3 analysts covering Kiora Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$38.8m in 2023. New consensus forecast suggests the company will make a loss of US$17.8m in 2023. お知らせ • Sep 09
EyeGate Pharmaceuticals, Inc. Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation EyeGate Pharmaceuticals, Inc. announced that it has completed target enrollment of 21 patients in the Phase 2 proof-of-concept (‘POC’) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (“DHODH”) and is first-in-class for ophthalmology indications. The randomized, double-masked, placebo-controlled POC study conducted at a site in Vienna, Austria is designed to evaluate the safety, tolerability, and efficacy of PP-001 in patients with ocular surface inflammation due to dry eye disease. In this study, a total of 21 patients are treated for 12 days with 0.15% of PP-001 or placebo. An IND filing for dry eye disease in the U.S. is expected in fourth quarter of 2021. PP-001 is a novel, non-steroidal immunomodulatory small molecule. PP-001 is a highly specific nanomolar potent inhibitor of DHODH, an essential enzyme of the de novo pyrimidine pathway. Inhibition of this pathway also downregulates expression of IFN-y and IL-17, two hallmark cytokines of Th1 and Th17 cells responsible for inflammatory diseases of the eye. Further, PP-001 reduces the host cell pyrimidine pool, which leads to inhibition of replication of activated immune cells. お知らせ • Aug 12
EyeGate Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10.750013 million. EyeGate Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10.750013 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 4,668,844
Price\Range: $2.3025
Discount Per Security: $0.1612
Transaction Features: Registered Direct Offering Executive Departure • Aug 05
Director Steven Boyd has left the company On the 3rd of August, Steven Boyd's tenure as Director ended after 3.2 years in the role. We don't have any record of a personal shareholding under Steven's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Aug 05
Director I. Maher has left the company On the 3rd of August, I. Maher's tenure as Director ended after 1.6 years in the role. We don't have any record of a personal shareholding under Maher's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. お知らせ • Jun 15
EyeGate Pharmaceuticals, Inc. Announces First Patient Dosed for PP-001 in A Phase 2 Proof-Of-Concept Ocular Surface Inflammation Study EyeGate Pharmaceuticals, Inc. announced the first patient dosed in phase II proof-of-concept (“POC”) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (“DHODH”) and is first-in-class for ophthalmology indications. The randomized, double-masked, placebo-controlled POC study will be conducted at a site in Vienna, Austria and is designed to evaluate the safety, tolerability and efficacy of PP-001 in patients with ocular surface inflammation due to dry eye disease. A total of 21 patients will receive 0.15% of PP-001 or placebo for 12 days. The outcome of this study will guide the U.S. clinical development program for dry eye disease following the filing of the IND, which is expected in Fourth Quarter 2021. PP-001 is a novel, non-steroidal immunomodulatory small molecule. PP-001 is a highly specific nanomolar potent inhibitor of DHODH, an essential enzyme of the de novo pyrimidine pathway. Inhibition of this pathway also downregulates expression of IFN-? and IL-17, two hallmark cytokines of Th1 and Th17 cells responsible for inflammatory diseases of the eye. Further, PP-001 reduces the host cell pyrimidine pool, which leads to inhibition of replication of activated immune cells. Breakeven Date Change • May 14
No longer forecast to breakeven The 2 analysts covering EyeGate Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$28.4m in 2022. New consensus forecast suggests the company will make a loss of US$3.90m in 2022. Is New 90 Day High Low • Feb 06
New 90-day high: €6.00 The company is up 117% from its price of €2.76 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 14% over the same period. Is New 90 Day High Low • Jan 13
New 90-day high: €5.45 The company is up 72% from its price of €3.16 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 14% over the same period. お知らせ • Dec 23
EyeGate Pharmaceuticals, Inc. (NasdaqCM:EYEG) entered into a share purchase agreement to acquire Panoptes Pharma GES.M.B.H for $15 million. EyeGate Pharmaceuticals, Inc. (NasdaqCM:EYEG) entered into a share purchase agreement to acquire Panoptes Pharma GES.M.B.H for $15 million on December 18, 2020. Consideration is comprised of (i) 884,222 shares of EyeGate common stock (ii) 45.8923 shares of the Company’s Series D Convertible Preferred Stock (the “Series D Preferred Stock”) convertible, subject to stockholder approval, into an aggregate of 13,000 shares of common stock, and (iii) cash payments in an aggregate amount of approximately $0.220577 million. Additionally, 1,500 shares of Series D Preferred Stock convertible into an aggregate of approximately 424,685 shares of common stock will be issued after a period of 18 months subject to adjustments for potential post-closing working capital and/or indemnification claims relating to breaches of representations, warranties and covenants contained in the Purchase Agreement. At the closing, EyeGate paid off indebtedness of Panoptes equal to €0.1 ($0.12255) million and will be required to repay an additional €0.2 ($0.2451) million by December 31, 2021. In addition, the Sellers are eligible to receive up to $9.5 million in milestone payments, with $4.75 million being payable upon the enrollment and randomization of a first patient into the first Phase III pivotal study of a Panoptes product with the U.S. Food and Drug Administration (the “FDA”) and $4.75 million being payable upon approval of the first New Drug Application by the FDA with respect to a Panoptes product, subject to certain set-off rights as descried in the Purchase Agreement. In each case, EyeGate may elect to pay the applicable milestone payment either (i) in cash, or (ii) by issuing shares of Series D Preferred Stock. Under the terms of the agreement, Panoptes will become a wholly owned subsidiary of EyeGate. As a part of transaction, Franz Obermayr, co-founder and Chief Executive Officer of Panoptes will join management team of EyeGate as EVP Clinical Development and Stefan Sperl will join management team of EyeGate as EVP CMC and Operations. Is New 90 Day High Low • Dec 22
New 90-day high: €4.30 The company is up 33% from its price of €3.24 on 23 September 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Analyst Estimate Surprise Post Earnings • Nov 11
Revenue in line with expectations Revenue was in line with analyst estimates. Is New 90 Day High Low • Nov 04
New 90-day low: €2.88 The company is down 16% from its price of €3.44 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Oct 19
New 90-day low: €3.04 The company is down 28% from its price of €4.24 on 21 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 
